Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Journal of Immunology (Baltimore, Md. : 1950)|July 20, 2010
Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognitionDavid K Cole, Emily S J Edwards, Katherine K Wynn, et al.Cancer Immunology, Immunotherapy : CII|December 25, 2012
Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumorsEmmet McCormack, Katherine J Adams, Namir J Hassan, et al.Protein & Cell|January 8, 2011
High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activationRuth K Moysey, Yi Li, Samantha J Paston, et al.Plos One|October 16, 2018
An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) moleculesJane Harper, Katherine J Adams, Giovanna Bossi, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 2, 2021
Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-βJonathan D Silk, Rachel J M Abbott, Katherine J Adams, et al.Science Translational Medicine|August 9, 2013
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cellsBrian J Cameron, Andrew B Gerry, Joseph Dukes, et al.Nature Medicine|May 8, 2012
Monoclonal TCR-redirected tumor cell killingNathaniel Liddy, Giovanna Bossi, Katherine J Adams, et al.Pageof 1